US 12,478,623 B2
Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
Robert E. Davis, San Diego, CA (US); Gretchen Snyder, New York, NY (US); and Peng Li, New Milford, NJ (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Appl. No. 17/764,070
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
PCT Filed Sep. 25, 2020, PCT No. PCT/US2020/052923
§ 371(c)(1), (2) Date Mar. 25, 2022,
PCT Pub. No. WO2021/062307, PCT Pub. Date Apr. 1, 2021.
Claims priority of provisional application 62/906,042, filed on Sep. 25, 2019.
Prior Publication US 2022/0362241 A1, Nov. 17, 2022
Int. Cl. A61K 31/4985 (2006.01); A61K 45/06 (2006.01); A61P 25/08 (2006.01); C07D 471/16 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 45/06 (2013.01); A61P 25/08 (2018.01); C07D 471/16 (2013.01)] 12 Claims
 
1. A pharmaceutical composition comprising (i) an effective amount of a a Compound of Formula I:

OG Complex Work Unit Chemistry
wherein:
X is —N(CH3)—;
Y is —C(═O)—;
in free, or pharmaceutically acceptable salt form and (ii) an effective amount of a nitric oxide donor.